vs

Side-by-side financial comparison of BayFirst Financial Corp. (BAFN) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $10.3M, roughly 1.9× BayFirst Financial Corp.). BayFirst Financial Corp. runs the higher net margin — -55.0% vs -177.4%, a 122.4% gap on every dollar of revenue. Over the past eight quarters, STANDARD BIOTOOLS INC.'s revenue compounded faster (-12.2% CAGR vs -29.6%).

The PNC Financial Services Group, Inc. is an American bank holding company and financial services corporation based in Pittsburgh, Pennsylvania. Its banking subsidiary, PNC Bank, operates in 27 states and the District of Columbia, with 2,629 branches and 9,523 ATMs. PNC Bank is one of the largest banks in the US by assets and by number of branches, deposits, and ATMs.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

BAFN vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.9× larger
LAB
$19.6M
$10.3M
BAFN
Higher net margin
BAFN
BAFN
122.4% more per $
BAFN
-55.0%
-177.4%
LAB
Faster 2-yr revenue CAGR
LAB
LAB
Annualised
LAB
-12.2%
-29.6%
BAFN

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
BAFN
BAFN
LAB
LAB
Revenue
$10.3M
$19.6M
Net Profit
$-5.7M
$-34.7M
Gross Margin
48.5%
Operating Margin
-168.5%
Net Margin
-55.0%
-177.4%
Revenue YoY
-11.5%
Net Profit YoY
-130.6%
-28.8%
EPS (diluted)
$-1.48
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BAFN
BAFN
LAB
LAB
Q1 26
$10.3M
Q4 25
$11.2M
Q3 25
$10.2M
$19.6M
Q2 25
$23.1M
$21.8M
Q1 25
$19.8M
$40.8M
Q4 24
$32.9M
Q3 24
$21.7M
$22.1M
Q2 24
$20.8M
$22.5M
Net Profit
BAFN
BAFN
LAB
LAB
Q1 26
$-5.7M
Q4 25
$-2.5M
Q3 25
$-18.9M
$-34.7M
Q2 25
$-1.2M
$-33.5M
Q1 25
$-335.0K
$-26.0M
Q4 24
$9.8M
Q3 24
$1.1M
$-26.9M
Q2 24
$866.0K
$-45.7M
Gross Margin
BAFN
BAFN
LAB
LAB
Q1 26
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Operating Margin
BAFN
BAFN
LAB
LAB
Q1 26
Q4 25
-25.3%
Q3 25
-253.0%
-168.5%
Q2 25
-7.1%
-118.1%
Q1 25
-2.3%
-80.8%
Q4 24
Q3 24
7.1%
-120.9%
Q2 24
5.9%
-134.5%
Net Margin
BAFN
BAFN
LAB
LAB
Q1 26
-55.0%
Q4 25
-22.1%
Q3 25
-184.7%
-177.4%
Q2 25
-5.3%
-153.7%
Q1 25
-1.7%
-63.8%
Q4 24
91.8%
Q3 24
5.2%
-122.0%
Q2 24
4.2%
-203.3%
EPS (diluted)
BAFN
BAFN
LAB
LAB
Q1 26
$-1.48
Q4 25
$-0.71
Q3 25
$-4.66
$-0.09
Q2 25
$-0.39
$-0.09
Q1 25
$-0.17
$-0.07
Q4 24
$2.21
Q3 24
$0.18
$-0.07
Q2 24
$0.12
$-0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BAFN
BAFN
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$134.5M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$81.9M
$399.7M
Total Assets
$1.2B
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BAFN
BAFN
LAB
LAB
Q1 26
$134.5M
Q4 25
$207.0M
Q3 25
$118.5M
$129.4M
Q2 25
$77.3M
$158.6M
Q1 25
$63.2M
$150.9M
Q4 24
$77.8M
Q3 24
$64.4M
$210.6M
Q2 24
$60.8M
$269.8M
Total Debt
BAFN
BAFN
LAB
LAB
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Stockholders' Equity
BAFN
BAFN
LAB
LAB
Q1 26
$81.9M
Q4 25
$87.6M
Q3 25
$89.7M
$399.7M
Q2 25
$108.2M
$424.5M
Q1 25
$110.1M
$454.6M
Q4 24
$110.9M
Q3 24
$102.3M
$489.3M
Q2 24
$101.0M
$510.3M
Total Assets
BAFN
BAFN
LAB
LAB
Q1 26
$1.2B
Q4 25
$1.3B
Q3 25
$1.3B
$539.6M
Q2 25
$1.3B
$557.0M
Q1 25
$1.3B
$579.6M
Q4 24
$1.3B
Q3 24
$1.2B
$681.5M
Q2 24
$1.2B
$708.7M
Debt / Equity
BAFN
BAFN
LAB
LAB
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BAFN
BAFN
LAB
LAB
Operating Cash FlowLast quarter
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BAFN
BAFN
LAB
LAB
Q1 26
Q4 25
$285.3M
Q3 25
$47.3M
$-22.2M
Q2 25
$63.3M
$-20.7M
Q1 25
$74.2M
$-30.3M
Q4 24
$390.5M
Q3 24
$90.8M
$-27.9M
Q2 24
$78.8M
$-39.0M
Free Cash Flow
BAFN
BAFN
LAB
LAB
Q1 26
Q4 25
$285.0M
Q3 25
$47.3M
$-23.1M
Q2 25
$63.1M
$-22.6M
Q1 25
$74.1M
$-35.3M
Q4 24
$388.8M
Q3 24
$90.5M
$-30.1M
Q2 24
$78.4M
$-41.0M
FCF Margin
BAFN
BAFN
LAB
LAB
Q1 26
Q4 25
2554.2%
Q3 25
462.2%
-118.1%
Q2 25
272.7%
-103.6%
Q1 25
375.1%
-86.6%
Q4 24
1180.9%
Q3 24
416.5%
-136.4%
Q2 24
376.1%
-182.2%
Capex Intensity
BAFN
BAFN
LAB
LAB
Q1 26
Q4 25
2.7%
Q3 25
0.1%
4.5%
Q2 25
0.8%
8.7%
Q1 25
0.4%
12.4%
Q4 24
5.1%
Q3 24
1.5%
10.2%
Q2 24
1.9%
8.6%
Cash Conversion
BAFN
BAFN
LAB
LAB
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
39.95×
Q3 24
79.85×
Q2 24
90.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BAFN
BAFN

Net Interest Income$9.4M91%
Noninterest Income$884.0K9%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons